These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 24955702)

  • 1. Risks and benefits of phase 1 clinical trial participation.
    Mahipal A; Nguyen D
    Cancer Control; 2014 Jul; 21(3):193-9. PubMed ID: 24955702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of cohort-specific consent and patient control in phase I cancer trials.
    Daugherty CK; Ratain MJ; Minami H; Banik DM; Vogelzang NJ; Stadler WM; Siegler M
    J Clin Oncol; 1998 Jul; 16(7):2305-12. PubMed ID: 9667244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The project data sphere initiative: accelerating cancer research by sharing data.
    Green AK; Reeder-Hayes KE; Corty RW; Basch E; Milowsky MI; Dusetzina SB; Bennett AV; Wood WA
    Oncologist; 2015 May; 20(5):464-e20. PubMed ID: 25876994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials.
    Roberts TG; Goulart BH; Squitieri L; Stallings SC; Halpern EF; Chabner BA; Gazelle GS; Finkelstein SN; Clark JW
    JAMA; 2004 Nov; 292(17):2130-40. PubMed ID: 15523074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hope for a cure and altruism are the main motives behind participation in phase 3 clinical cancer trials.
    Godskesen T; Hansson MG; Nygren P; Nordin K; Kihlbom U
    Eur J Cancer Care (Engl); 2015; 24(1):133-41. PubMed ID: 24467443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "It is not guaranteed that you will benefit": True but misleading?
    Kim SY; Wilson R; De Vries R; Kim HM; Holloway RG; Kieburtz K
    Clin Trials; 2015 Aug; 12(4):424-9. PubMed ID: 25963311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evaluation of the risks and benefits of phase II cancer clinical trials by institutional review board (IRB) members: a case study.
    van Luijn HE; Aaronson NK; Keus RB; Musschenga AW
    J Med Ethics; 2006 Mar; 32(3):170-6. PubMed ID: 16507666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology.
    Alexander KP; Newby LK; Cannon CP; Armstrong PW; Gibler WB; Rich MW; Van de Werf F; White HD; Weaver WD; Naylor MD; Gore JM; Krumholz HM; Ohman EM; ;
    Circulation; 2007 May; 115(19):2549-69. PubMed ID: 17502590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accrual to cancer clinical trials in the era of molecular medicine.
    Schilsky RL
    Sci Transl Med; 2011 Mar; 3(75):75cm9. PubMed ID: 21430267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of methodological issues of clinical trials in multiple sclerosis.
    Montalban X
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S35-42. PubMed ID: 22206765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and future roles of targeted therapy and immunotherapy in advanced melanoma.
    Olszanski AJ
    J Manag Care Spec Pharm; 2014 Apr; 20(4):346-56. PubMed ID: 24684639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of mitochondrial electron transport chain disorders: a review of clinical trials over the past decade.
    Kerr DS
    Mol Genet Metab; 2010 Mar; 99(3):246-55. PubMed ID: 20060349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current vaccination strategies for prostate cancer.
    Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
    Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials.
    Olmos D; Baird RD; Yap TA; Massard C; Pope L; Sandhu SK; Attard G; Dukes J; Papadatos-Pastos D; Grainger P; Kaye SB; de Bono JS
    Clin Cancer Res; 2011 Aug; 17(15):5188-96. PubMed ID: 21531820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perceptions of cancer patients and their physicians involved in phase I trials.
    Daugherty C; Ratain MJ; Grochowski E; Stocking C; Kodish E; Mick R; Siegler M
    J Clin Oncol; 1995 May; 13(5):1062-72. PubMed ID: 7738612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perceived benefits of and barriers to participation in a phase I/II colon cancer chemoprevention trial.
    Hudmon KS; Love RR; Chamberlain RM
    J Cancer Educ; 1999; 14(2):83-7. PubMed ID: 10397482
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.